Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.
Fiche publication
Date publication
janvier 2021
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr MOUILLET Guillaume, Pr HEYD Bruno, Dr VERNEREY Dewi, Dr VIENOT Angélique, Dr VUITTON Lucine, Dr JACQUINOT Quentin
Tous les auteurs :
d'Engremont C, Grillot J, Raillat J, Vernerey D, Vuitton L, Koch S, Turco C, Heyd B, Mouillet G, Jacquinot Q, Borg C, Vienot A
Lien Pubmed
Résumé
Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term survival in localized pancreatic ductal adenocarcinoma (LPDAC). Notwithstanding, recurrence occurs in the vast majority of patients and a better stratification of preoperative therapies is required. This study aimed to investigate preoperative immunological and nutritional factors to predict relapse-free survival (RFS) in patients with LPDAC.
Mots clés
lymphopenia, pancreatic ductal adenocarcinoma, preoperative, prognostic factor, sarcopenia
Référence
Front Oncol. 2021 ;11:683289